Abacus Life(US:ABL) Prnewswireยท2025-06-25 17:06Core Viewpoint - Abacus Global Management is facing significant pressure as its stock price has dropped over 36% in the past month due to serious allegations from Morpheus Research regarding financial misconduct and questionable accounting practices [1][5]. Group 1: Allegations and Investigations - Morpheus Research, a new investigative group with ties to Hindenburg Research, published reports accusing Abacus of manipulating its life settlements portfolio through aggressive accounting practices, leading to inflated asset values and "fake revenue" [3][4]. - Hagens Berman, a prominent law firm, has initiated its own investigation into the claims made by Morpheus Research, urging affected shareholders to report their financial losses [2][6]. - The scrutiny intensified after Morpheus's follow-up report alleged inconsistencies in Abacus's rebuttal and introduced claims of undisclosed related-party transactions [4]. Group 2: Company Response and Stock Performance - In response to the allegations, Abacus retained independent actuarial firm Lewis & Ellis to review its balance sheet and reassure investors of compliance with accounting standards [4]. - Despite the company's efforts, including a $20 million share repurchase program aimed at restoring investor confidence, the stock has continued to trade near its 52-week low [5][6]. - The stock experienced a sharp 20% drop in a single day following the initial report from Morpheus [3].